{'fraction_non_alphanumeric': 0.015625, 'fraction_numerical': 0.0, 'mean_word_length': 5.568376068376068, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Update on the pathogenesis and management of childhood asthma

Purpose of review To review and summarize trends in the current literature in childhood asthma with implications for current management and future research. Recent findings There have been several articles in the last year that address the pathogenesis and pharmacogenomics of asthma. Recent consensus guidelines have been published that emphasize a stepwise approach to management, which will be briefly reviewed here. Several publications have proposed novel treatments to attempt to attenuate asthmatic lower airway inflammation. In terms of measuring this inflammation, a portable exhaled nitric oxide analyzer has been developed. Summary Evidence shows that various early life exposures (high house dust mite levels, early antibiotic use) may predispose susceptible individuals to the development of asthma, but the early introduction of solid foods, even so-called allergenic foods, does not appear to be one of these factors. Newly identified pharmacogenomic markers may be the first step in tailoring each asthmatic patient's therapy on the basis of genotype, and management tailored specifically toward each patient's level of airway inflammation is already coming into wider clinical use. Several novel treatments for asthma have shown promise in early studies. On the basis of the most recent evidence, the National Education and Prevention Program's Guidelines for the Diagnosis and Management of Asthma is a comprehensive, stepwise management guide for asthma.